Prevalence, symptom and severity of COVID 19 among permanent residents of Dhaka City

Yıl 2022, Cilt: 2 Sayı: 2, 73 - 80, 24.04.2022

Shamima Parvin Lasker Shah Mahfuzur Rahman Md Jafurullah Md Abdul Jalil Ansari Arif Hossain

Öz

A study was done on 385 people who survived from COVID 19 to assess the prevalence, symptom, and severity of COVID 19 of permanent residents of Dhaka city, Bangladesh during the second wave of corona manifestation. Data were collected purposively from a government and a private hospital, and general people taking treatment from home. A significant number of respondents took treatment from the Hospital during 2nd wave of COVID 19. Two-third of participants endured moderate (67.5%) type of suffering followed by mild (18.7%) and severe (13.8%) type of suffering. Most of the participants were married (88.8%) and female (51.2%). There was no significant difference between females and males suffering and the risk and severity of COVID 19 (p=694). Most of the participants (70%) had comorbidity. Time to recover from symptoms had significant relation with symptom patterns. One-third of the respondents (33%) required 4-7 days to recover from suffering. A little higher than a quarter (27.8%) recovered within 8 to 14 days and more than a quarter 105 (27.3%) recovered by 8-12 days respectively. Most of the respondents had a fever, cough, body ache and fatigue, sore throat, and breathing difficulty. Only (7.3%) had diarrhea (3.9%) and smell loss 13 (3.4%). People of permanent residence of Dhaka city suffered from COVID 19 irrespective of sex, education, professional status. They had comorbidity, required 8-14 days of hospitalization, and endured the moderate type of suffering of COVID-19.

Anahtar Kelimeler

COVID-19 pandemic, stuation of COVID 19, second wave, Dhaka city, Bangladesh

Kaynakça

• 1. Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. Glob Health Res Policy. 2020;5(6):1-3. doi: 10.1186/s41256-020-00135-6.
• 2. Munster VJ, Koopmans M, Doremalen VN, Riel VD, Wit DE. A novel coronavirus emerging in China. Key questions for impact assessment. N Engl J Med. 2020;382:692-4. doi: 10.1056/NEJMp2000929.
• 3. WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020 https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19.
• 4. The Straits Times. Bangladesh confirms first three cases of coronavirus. https://www.straitstimes.com/asia/south-asia/bangladesh-confirms-first-three-cases-o-coronavirus (Access on March 2020).
• 5. Worldometer.https://www.worldometers.info/coronavirus/ (Access on December 18, 2021).
• 6. Nazneen A, Sultana R, Rahman M, Rahman M, Qadri F, Rimi NA et al. Prevalence of COVID-19 in Bangladesh, April to October 2020 - a cross-sectional study. IJID Regions. 2021;1:92-9. doi: 10.1016/j.ijregi.2021.10.003.
• 7. Hossain I, Mullick AR, Khan MH, Halim KS, Aktaruzzaman MM, Nabi SG, et al. Comorbidity and its impact on COVID-19 affected patients in COVID-19 dedicated hospital of Bangladesh. Bangladesh Med J. 2021;49(1):19-25. doi: 10.3329/bmj.v49i1.52585.
• 8. Siam MHB, Hasan MM, Tashrif SM, Khan MHR, Raheem E, Hossain MS. Insights into the first seven-months of COVID-19 pandemic in Bangladesh: Lessons learned from a high-risk country. Heliyon. 2021;7(6):1-10. doi: 10.1016/j.heliyon.2021.e07385.
• 9. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: Focus on severity and mortality. Front Public Health. 2020;8:152. doi: 10.3389/fpubh.2020.00152.
• 10. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303-10. doi: 10.1016/j.dsx.2020.04.004.
• 11. Çilekar S, Balcı, A, İbrahim CG. Is Covid-19 responsible for asthma and COPD exacerbations? Health Sci. Q. 2022;2(1):17-25. doi: 10.26900/hsq.2.1.03.
• 12. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW et al . Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-9. doi: 10.1001/jama.2020.6775.
• 13. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. IJID. 2020;94:91-5. doi: 10.1016/j.ijid.2020.03.01.
• 14. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-8. doi: 10.1001/jamacardio.2020.1017.
• 15. Pablo GB, Valerio C, and, Ericka R. Gender differences in altruism on Mechanical Turk: Expectations and actual behaviour. Economics Letters. 2018;170:19-23. doi: 10.1016/j.econlet.2018.05.022.
• 16. WHO. Gender and COVID-19. World Health Organization; 2020 advocacy brief, 14 May 2020 https://apps.who.int/iris/ bitstream/handle/10665/332080/WHO-2019-nCoV-Advocacy_brief-Gender-2020.1-eng.pdf?sequence=1&isAllowed=y (Access on December 14 2021)
• 17. Barua UK, Saha SK, Ghosh DK, Ruble MMK. Epidemiological study on bronchial asthma at Shaheed Suhrawardy Medical College Hospital, Dhaka. J Shaheed Suhrawardy Med Coll. 2013;5(2):77-80. doi: 10.3329/jssmc.v5i2.20759.
• 18. Torres RM, Souza MDS, Coelho ACC, de Mello LM, Machado CZ. Association between asthma and Type 2 diabetes mellitus: Mechanisms and impact on asthma control - A Literature Review. Can. Respir J. 2021:8830439. doi: 10.1155/2021/8830439.
• 19. Rogala B, Bożek A, Gluck J. Is there a relationship between asthma and diabetes? J Asthma. 2020;57(12):1332-8. doi: 10.1080/02770903.2019.1652642.